Drugs / octavalent HPV Vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00260039 | Dec 2005 → Aug 2007 | anogenital human papillomavirus infection, cervical cancer | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | octavalent HPV Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00260039 ↗ |
| Modality | Vaccine | “octavalent Human Papillomavirus (HPV) L1 Virus-like Particle (VLP) Vaccine” NCT00260039 ↗ |
| Route | Intramuscular | “0.5 mL octavalent HPV vaccine - intramuscular injection administered at Day 1, Month 2 and Month 6” NCT00260039 ↗ |